Delving into the Latest Updates on Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Skin and Musculoskeletal Diseases

Infectious Diseases

Fusion protein

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Infectious Diseases	1

Top 5 Drug Type	Count

Bispecific antibody	1
Fusion protein	1

Top 5 Target	Count

IL-17A x albumin	1
IL-23p19 x TNF-α	1

Background:Atypical peaks were observed in capillary electrophoresis with sodium dodecyl sulfate (CE-SDS) during the development of therapeutic monoclonal IgG4 antibodies (mAb-X). Based on the previous literature reports, the atypical peak may be caused by various factors such as post-translational modifications (PTMs), method-induced artifacts, sample degradation and sequence variants. Due to the high complexity structure of mAbs and the limitations of CE-SDS, acquiring comprehensive profiling of atypical peaks has historically been challenging.Objective:Here we developed a strategy utilizing complementary analytical methods to identify the cause of atypical peak.Methods:This strategy includes optimizing reduced CE-SDS method to evaluate artifacts induced by the analytical method, excluding potential glycation modifications, and utilizing Liquid Chromatograph Mass Spectrometer (LC-MS) to characterize mAb-X.Results:Our study demonstrates that the atypical peaks of mAb-X are a mixture of method-induced artifacts and variants in the C-terminal extension sequence of the light chain.Conclusion:Strategy for complementary analytical methods tools helps to identify the cause of unknown species and plays a key role in product and process characterization.

01 May 2023·B31. ASTHMA: FROM MICE TO MEN, AND BACK AGAIN

Enhanced Blocking toward TSLP Variants at Lung Barrier Protects against Experimental Asthma

Author: Wu, X. ; Li, Y. ; Guo, C. ; Lei, R. ; Fan, P. ; Wang, J.J. ; Fan, L.

100 Deals associated with Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

IND Application

IND Approval

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IMG-007 ( OX40 )	Dermatitis, Atopic More	IND Approval
IMG-004 ( BTK )	Chronic Urticaria More	IND Approval
Izokibep ( IL-17A x albumin )	-	IND Application
Anti-TNFα/IL23p19 bispecific antibody(Inmagene) ( IL-23p19 x TNF-α )	Autoimmune Diseases More	Preclinical